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Introduction
The Sir2 protein deacetylase has emerged as an important reg-
ulator of aging in yeast, Caenorhabditis elegans, and Drosoph-
ila  melanogaster  (Guarente  and  Picard,  2005;  Longo  and 
Kennedy, 2006). The conserved role of Sir2 in extending life 
span in lower organisms raises the possibility that the mamma-
lian orthologue of Sir2 may also play a similar role. In mam-
mals, there are seven homologues of Sir2, SIRT1–7, of which 
SIRT1 is most similar to the yeast Sir2 and is considered to be 
the orthologue of yeast Sir2. SIRT1 has been shown to regulate 
multiple cellular functions, including cellular stress response, 
cell differentiation, development, and metabolism (Michan and 
Sinclair, 2007). Activators of SIRT1 improve cellular mito-
chondria function and protect mice from metabolic diseases 
(Baur et al., 2006; Lagouge et al., 2006; Milne et al., 2007). 
Furthermore,  SIRT1  transgenic  mice  also  display  beneficial 
phenotypes similar to mice on a calorie-restricted diet (leaner 
and more metabolically active; Bordone et al., 2007), support-
ing an antiaging role of SIRT1.
Recent studies also revealed a paradoxical role of SIRT1 
in tumorigenesis, possibly as a result of SIRT1’s inhibitory ef-
fect toward tumor suppressors such as p53. Inhibition of SIRT1 
by small molecule inhibitors or down-regulation of SIRT1 by 
siRNA results in arrested cell growth and apoptosis in several 
tumor cell lines, including breast, lung, and colon cancer lines, 
suggesting a role for SIRT1 in tumor cell growth (Ford et al., 
2005; Heltweg et al., 2006; Ota et al., 2006; Lain et al., 2008). 
In addition, inhibition of SIRT1 results in reactivation of tumor 
suppressor gene transcription in human breast and colon cancer 
lines (Pruitt et al., 2006), suggesting a role for SIRT1 in silenc-
ing tumor suppressor genes. Together, these studies suggest a 
possible role of SIRT1 in promoting tumorigenesis. However, 
recent work with SIRT1 transgenic and knockout mice also sug-
gests a role for SIRT1 in tumor suppression (Firestein et al., 
2008; Wang et al., 2008). Therefore, the biological effects of 
SIRT1 are complex. In this study, we show that c-Myc and 
SIRT1 form a negative feedback loop that inhibits c-Myc–induced 
cellular transformation. These results support a tumor suppres-
sion function of SIRT1.
Results and discussion
During our investigation of SIRT1 regulation, we found that 
there are three potential c-Myc–binding sites (E-box) localized 
at the SIRT1 promoter. This finding led us to hypothesize that 
c-Myc may regulate SIRT1 expression. Indeed, overexpression 
of  c-Myc  increased  SIRT1  expression  (Fig.  1  a).  However, 
down-regulation of c-Myc decreased SIRT1 expression (Fig. 1 b). 
Furthermore, SIRT1 expression is higher in c-Myc–proficient 
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he protein deacetylase SIRT1 has been implicated in 
a  variety  of  cellular  functions,  including  develop-
ment, cellular stress responses, and metabolism. In-
creasing evidence suggests that similar to its counterpart, 
Sir2, in yeast, Caenorhabditis elegans, and Drosophila 
melanogaster, SIRT1 may function to regulate life span in 
mammals. However, SIRT1’s role in cancer is unclear. Dur-
ing our investigation of SIRT1, we found that c-Myc binds 
to the SIRT1 promoter and induces SIRT1 expression. 
However, SIRT1 interacts with and deacetylates c-Myc, re-
sulting in decreased c-Myc stability. As a consequence, 
c-Myc’s transformational capability is compromised in the 
presence of SIRT1. Overall, our experiments identify a   
c-Myc–SIRT1 feedback loop in the regulation of c-Myc 
activity and cellular transformation, supporting/suggesting 
a role of SIRT1 in tumor suppression.
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it is possible that SIRT1 could regulate c-Myc activity by 
deacetylating c-Myc. As shown in Fig. 2 d, overexpression of 
wild-type (WT) SIRT1, but not catalytically inactive SIRT1-
H363Y, resulted in hypoacetylation of c-Myc. Conversely, 
down-regulation of SIRT1 using SIRT1 siRNA resulted in c-Myc 
hyperacetylation (Fig. 2 e). Finally, SIRT1
/ cells showed that 
c-Myc hyperacetylation compared with SIRT1
+/+ cells; recon-
stitution of SIRT1
/ cells with WT SIRT1, but not inactive 
SIRT1-H363Y, decreased c-Myc acetylation (Fig. 2 f). These 
results suggest that SIRT1 deacetylates c-Myc in cells.
We further explored potential SIRT1 deacetylation sites of 
c-Myc. Previous studies have identified several potential acety-
lation sites of c-Myc (Patel et al., 2004; Faiola et al., 2005).   
We found that Lys323 (K323) is a major SIRT1 deacetylation 
site because overexpression of SIRT1 was unable to reduce   
c-MycK323R acetylation as it was with the WT c-Myc. Thus, 
although the c-MycK232R mutant is not able to be acetylated, 
SIRT1 overexpression was not able to reduce the acetylation 
status of the mutant below that of basal levels (Fig. 2 g). Con-
firming this result, the loss of SIRT1 did not increase acetyla-
tion levels of the K323R mutant (Fig. 2 h). These results suggest 
that K323 of c-Myc is the major SIRT1 deacetylation site.
c-Myc has previously been shown to be acetylated, which 
enhances c-Myc stability (Vervoorts et al., 2003; Patel et al., 
2004; Faiola et al., 2005). Because SIRT1 deacetylates c-Myc, 
we hypothesized that SIRT1 affects c-Myc stability. In support 
of our hypothesis, overexpression of SIRT1 decreased the   
fibroblasts (TGR and Myc3) than that of Myc-deficient cells 
(HO15; Fig. 1 c). These results suggest that c-Myc may act to 
enhance SIRT1 expression. To investigate whether c-Myc regu-
lates  SIRT1  expression  at  the  transcriptional  level,  we  per-
formed quantitative RT-PCR (QRT-PCR) of SIRT1 transcripts. 
As shown in Fig. 1 d, there were more SIRT1 transcripts in   
c-Myc–proficient cells than those of c-Myc–deficient cells, sug-
gesting  that  c-Myc  induces  SIRT1  transcription.  Finally,  to 
directly demonstrate that c-Myc binds at the SIRT1 promoter, 
we performed chromatin immunoprecipitation (ChIP) assays 
using anti–c-Myc antibodies. As shown in Fig. 1 e, Myc binds 
one E-box (E1) but not other E-boxes (E2 and E3) of the SIRT1 
promoter.  Overall,  our  results  suggest  that  c-Myc  promotes 
SIRT1 expression by elevating SIRT1 transcription.
Interestingly, we also found that SIRT1 coimmunoprecip-
itated with c-Myc in vivo (Fig. 2 a). To confirm the specificity 
of this interaction, we used SIRT1 siRNA to down-regulate 
SIRT1. c-Myc failed to coimmunoprecipitate with SIRT1 in 
cells transfected with SIRT1 siRNA (Fig. 2 a), confirming the 
specificity of the c-Myc–SIRT1 interaction. Furthermore, immuno-
precipitation of c-Myc also pulled down SIRT1 (Fig. 2 b).   
To examine whether the SIRT1–c-Myc interaction is direct, we 
incubated purified c-Myc and SIRT1 under cell-free conditions 
and found that SIRT1 interacts with c-Myc in vitro, suggesting 
that SIRT1 directly interacts with c-Myc (Fig. 2 c).
We next investigated the functional significance of the 
c-Myc–SIRT1 interaction. Because SIRT1 is a protein deacetylase, 
Figure 1.  c-Myc induces SIRT1 expression. (a) Control vector or constructs encoding Flag–c-Myc were transfected into 293T cells. 48 h later, cell lysates 
were examined by Western blotting. (b) HeLa cells were transfected with control (ctrl) shRNA or c-Myc shRNA. 72 h later, proteins were examined by 
Western blotting. (c) HO15 (c-Myc
/), TGR (c-Myc
+/+), and Myc3 (HO15 cells reconstituted with c-Myc) were lysed, and the cell lysates were subjected 
to Western blotting. (d) mRNA from HO15 and Myc3 were subjected to QRT-PCR. Values represent the relative induction of SIRT1 mRNA normalized to 
GAPDH. Data represent the mean of three determinations ± SEM. **, P < 0.01 by two-tailed Student’s t test. (e) ChIP assays were performed using anti– 
c-Myc antibody. The TERT and nucleolin promoter primers were used as a positive control, and SIRT1 intron 7 primers were used as a negative control.205 SIRT1 NEGATIVELY REGULATES c-Myc • Yuan et al.
Figure 2.  SIRT1 interacts with c-Myc and deacetylates c-Myc at K323. (a and b). HeLa cells were transfected with control (ctrl) or SIRT1 siRNA (a) or left 
untransfected (b). Cell lysates were subjected to immunoprecipitation (IP) and immunoblotting with the indicated antibodies. (c) Purified Flag-SIRT1 was 
incubated with recombinant GST or GST–c-Myc coupled to glutathione-Sepharose. Proteins retained on the beads were blotted with the indicated antibodies. 
(d) The indicated constructs were transfected into 293T cells. 48 h later, cell lysates were subjected to immunoprecipitation and immunoblotting with the 
indicated antibodies. (e) Cells were transfected with control or SIRT1 siRNA. 72 h later, the acetylation (Ac) level of c-Myc was detected as in d. (f) SIRT1
+/+, 
SIRT1
/, and SIRT1
/ reconstituted with SIRT1 and SIRT1-H363Y were lysed, and the acetylation level of c-Myc were detected as in d. (g) The indicated 
constructs were transfected into cells. 48 h later, cell lysates were subjected to immunoprecipitation and immunoblotting with the indicated antibodies.   
(h) SIRT1
+/+ and SIRT1
/ cells were transfected with the indicated expressing constructs. 48 h later, cell lysates were subjected to immunoprecipitation 
immunoblotting with the indicated antibodies. To compare the acetylation of c-Myc, the levels of c-Myc were equalized in d–h.JCB • VOLUME 185 • NUMBER 2 • 2009   206
Reconstitution  of  WT  SIRT1,  but  not  catalytically  inactive 
SIRT1, decreased c-Myc expression (Fig. S1 a). These results 
suggest that SIRT1 regulates c-Myc expression at the posttran-
scriptional level. We next examined whether SIRT1 regulates 
c-Myc stability in the presence of cycloheximide, which blocks 
protein translation. As shown in Fig. 3 d, overexpression of 
c-Myc protein level without affecting the c-Myc mRNA level 
(Fig. 3 a). Conversely, down-regulation of SIRT1 increased 
c-Myc expression with no effect on c-Myc transcripts (Fig. 3 b). 
To  confirm  these  findings,  we  used  SIRT1
+/+  and  SIRT1
/ 
mouse embryonic fibroblasts (MEFs). As shown in Fig. 3 c, 
there was increased expression of c-Myc in SIRT1
/ cells. 
Figure 3.  SIRT1 decreases c-Myc stability. (a) The indicated constructs were transfected into 293T cells. 48 h later, proteins and mRNA were extracted and 
subjected to Western blotting or QRT-PCR. (b) HeLa cells were transfected with control (ctrl) or SIRT1 siRNA. 72 h later, proteins and mRNA were extracted 
and subjected to Western blotting or QRT-PCR. (a and b) Quantification of c-Myc protein and transcript levels is shown in the bottom panels. (c) Cell lysates 
from SIRT1
+/+ or SIRT1
/ were blotted with the indicated antibodies. (bottom) Quantification of c-Myc protein levels is shown. (d) The indicated constructs 
were transfected into 293T cells. 20 h later, cells were treated with 0.1 mg/ml cycloheximide (CHX) and harvested at the indicated time. Immunoblots of   
c-Myc and -actin protein at the indicated times are shown. (right) Quantification of the c-Myc levels is shown. (e) SIRT1
+/+ and SIRT1
/ were transfected with 
the indicated constructs. c-Myc stability was then examined as in d. (right) Quantification of the Flag–c-Myc levels is shown. Error bars represent SEM.207 SIRT1 NEGATIVELY REGULATES c-Myc • Yuan et al.
(LDHA)  and  mitochondrial  serine  hydroxymethyltransferase 
(mSHMT) expression (Shim et al., 1997, 1998; Nikiforov et al., 
2002). We also found that SIRT1 decreased Myc-induced LDHA 
expression by Western analysis and both LDHA and mSHMT 
expression by QRT-PCR (Fig. 4 h; and Fig. S2, a and b, respec-
tively). Overall, these results strongly suggest that SIRT1 nega-
tively regulates c-Myc activity.
The inhibitory effect of SIRT1 on c-Myc raised the possibil-
ity that SIRT1 could negatively regulate cell growth and transfor-
mation. To specifically examine how SIRT1 affects c-Myc–induced 
cell growth, we used Myc
/ HO15 cells, and HO15 rat fibroblast 
cells stably reconstituted with c-Myc (Myc3). As shown in Fig. 5 a, 
expression of c-Myc greatly increased colony formation. How-
ever, coexpression of WT SIRT1, but not catalytically inactive 
SIRT1, with c-Myc significantly decreased c-Myc–induced col-
ony formation. Furthermore, we performed soft agar assays to ex-
amine how SIRT1 affects anchorage-independent cell growth. As 
shown in Fig. 5 b, Myc3 cells displayed anchorage-independent 
cell growth in soft agar. However, expression of SIRT1 signifi-
cantly decreased the colony formation in soft agar, whereas cata-
lytically inactive SIRT1 only slightly affected colony formation. 
These results suggest that SIRT1 inhibits c-Myc–dependent cel-
lular transformation. To confirm that SIRT1 suppresses cell 
growth by deacetylating c-Myc, we used the MycK323R mutant 
to perform cell growth experiments. As shown in Fig. 5 c, al-
though SIRT1 could suppress WT c-Myc and MycT58A-induced 
cell growth, it had no effect on MycK323R-induced cell growth. 
These results suggest that SIRT1 exerts its antitransformation ef-
fects  by  deacetylating  K323  of  Myc.  SIRT1  also  decreased 
MycT58A-induced cell growth and colony formation of FBW7
+/+ 
and FBW7
/ cells (Fig. S3 a), suggesting that SIRT1 regulates 
c-Myc activity independently of the FBW7 pathway.
Finally, to confirm the role of SIRT1 in suppressing cellu-
lar transformation in vivo, we stably expressed Ras and SIRT1 
in Myc3 cells. Cells were then implanted into athymic nude 
mice. As shown in Fig. 5 d and Fig. S3 b, overexpression of 
SIRT1 significantly inhibited tumorigenesis in nude mice. Col-
lectively, these results demonstrate a tumor suppression role of 
SIRT1 in vitro and in vivo.
In  this  study,  we  present  evidence  that  c-Myc  induces 
SIRT1 expression, and SIRT1 in turn deacetylates and down-
regulates c-Myc, resulting in decreased c-Myc target gene (i.e., 
TERT) expression and cellular transformation (Fig. 5 e). Conse-
quently, this Myc-SIRT1 negative feedback loop can restrain 
Myc’s transformational activities. Although it has been estab-
lished that SIRT1 has several important roles in metabolism and 
cellular stress response, its role in tumorigenesis remains con-
troversial because both pro- and antitumorigenesis effects of 
SIRT1 have been suggested. It is possible that SIRT1’s role in 
tumorigenesis is context dependent. For example, senescence is 
important for suppression of tumor initiation; however, it is 
thought to drive tumor growth by secreting inflammatory fac-
tors and tissue-disrupting enzymes (Campisi, 2005). It is possi-
ble that SIRT1 inhibits the initiation of tumor in premalignant 
cells by inhibiting c-Myc. However, cancer cells could become 
addicted to SIRT1 as a result of SIRT1’s antiapoptosic func-
tions. In support of this notion, inhibition of SIRT1 induces cell 
SIRT1 decreased c-Myc stability. Conversely, loss of SIRT1 ex-
pression enhanced c-Myc stability (Fig. S1 b). Reconstitution 
of SIRT1
/ cells with WT SIRT1, but not catalytically inactive 
SIRT1, restored the c-Myc half-life to the level of WT MEFs 
(Fig. S1 b). These results suggest that SIRT1 negatively regu-
lates c-Myc stability.
Previous studies have established that the F-box protein 
FBW7 binds to phospho-Thr58 of c-Myc and targets it to the 
SKP1–Cul1–F-box ubiquitin ligase complex for degradation 
(Welcker et al., 2004; Yada et al., 2004). It is possible that 
SIRT1 regulates c-Myc stability through FBW7. We used the 
MycT58A mutant to investigate this possibility. As shown in 
Fig. 3 e, MycT58A is more stable than WT c-Myc, which is 
consistent with previous findings (Welcker et al., 2004; Yada 
et al., 2004). However, SIRT1 still decreased MycT58A stabil-
ity, suggesting that SIRT1 and FBW7 regulate c-Myc stability 
through distinct pathways.
Because  we  have  shown  that  K323  is  a  major  SIRT1 
deacetylation site of c-Myc (Fig. 2, g and h), we further exam-
ined whether SIRT1 regulates c-Myc stability through K323. As 
shown in Fig. 3 e, MycK323 was less stable than WT c-Myc. 
Although SIRT1 decreased the stability of WT c-Myc, it had no 
effect  toward  MycK323R. These  results  suggest  that  SIRT1 
regulates c-Myc stability by deacetylating K323.
We next investigated how SIRT1 affects c-Myc function 
by examining the expression of c-Myc target genes. We first ex-
amined the expression of telomerase reverse transcriptase gene 
(TERT), which is a direct target gene of c-Myc (Greenberg   
et al., 1999; Wu et al., 1999). Consistent with its negative regu-
lation of c-Myc, overexpression of SIRT1 decreased TERT ex-
pression (Fig. 4 a). However, overexpression of the catalytically 
inactive SIRT1 mutant SIRT1-H363Y did not affect TERT 
expression. Furthermore, TERT expression is clearly higher in 
SIRT1
/ cells than that of SIRT1
+/+ cells (Fig. 4 b), confirming 
that SIRT1 negatively regulates TERT expression.
Because SIRT1 could regulate multiple transcriptional fac-
tors, we decided to confirm that SIRT1 regulates TERT expression 
through c-Myc. We found little expression of TERT in Myc
/ 
HO15  cells.  However,  HO15  cells  stably  reconstituted  with   
c-Myc (Myc3) showed enhanced TERT expression (Fig. 4 c). 
Importantly, overexpression of WT SIRT1, but not catalytically 
inactive SIRT1, suppressed TERT expression, suggesting that 
SIRT1 negatively regulates TERT expression through c-Myc.
To further confirm the inhibitory effects of SIRT1 toward 
c-Myc, we also examined the expression of other c-Myc target 
genes. c-Myc has been shown to activate cyclin B1 expression 
and suppress Gadd45 and p21 expression (Adhikary and Eilers, 
2005). We  found  increased  expression  of  cyclin  B1  and  de-
creased expression of Gadd45 and p21 in SIRT1
/ cells and 
cells transfected with SIRT1 siRNA (Fig. 4, d and e). However, 
overexpression  of  WT  SIRT1,  but  not  catalytically  inactive 
SIRT1, results in decreased cyclin B1 expression and increased 
Gadd45 and p21 expression (Fig. 4 f). Furthermore, QRT-PCR 
results showed increased transcripts of cyclin B1 and decreased 
transcripts of Gadd45 and p21 in SIRT1
/ cells (Fig. 4 g). In 
addition, Myc has also been shown to regulate cancer cell energy 
metabolism by inducing genes such as lactate dehydrogenase A JCB • VOLUME 185 • NUMBER 2 • 2009   208
which blocks Miz1 function and p21 and p16 transcription, 
thereby acting as a positive feedback loop to further potentiate 
Myc’s ability to promote cell growth (Wanzel et al., 2008). We 
showed that through a negative feedback loop, SIRT1 could de-
crease the expression of c-Myc target genes (e.g., TERT) and 
increase  expression  of  tumor  suppressors  (e.g.,  p21  and 
Gadd45). Our results are consistent with previous findings that 
SIRT1 can limit replicative life span (Chua et al., 2005) and 
TERT expression (Narala et al., 2008).
cycle arrest and death only in cancer cells but not noncancerous 
cells (Ford et al., 2005). Therefore, SIRT1 might have both 
tumor suppression and promotion roles depending on the stage 
of cell transformation.
Feedback mechanisms have previously been demonstrated 
for the regulation of Myc activity. For example, Myc induced 
expression of ribosomal protein L11, which in turn binds Myc 
and blocks Myc transcriptional activity (Dai et al., 2007), form-
ing a negative feedback loop. Myc also induces L23 expression, 
Figure 4.  SIRT1 inhibits Myc target gene expression through c-Myc. (a) 293T cells were transfected with the indicated constructs. 48 h later, cells were 
lysed, and cell lysates were blotted with the indicated antibodies. (b) Cell lysates from SIRT1
+/+ or SIRT1
/ MEFs were blotted with the indicated anti-
bodies. (c) HO15 and Myc3 cells were infected with retrovirus control or retrovirus encoding SIRT1 and SIRT1-H363Y. 48 h later, cells were lysed, and cell   
lysates were blotted with the indicated antibodies. (d) Cell lysates from SIRT1
+/+ and SIRT1
/ were blotted with the indicated antibodies. (e) HeLa cells 
were transfected with control (ctrl) or SIRT1 siRNA. 72 h later, cells were lysed, and cell lysates were blotted with the indicated antibodies. (f) 293T cells 
were transfected with the indicated constructs. 48 h later, cell lysates were blotted with the indicated antibodies. (g) SIRT1
+/+ and SIRT1
/ were lysed, 
and mRNA were extracted and subjected to QRT-PCR. Values represent the relative induction normalized to GAPDH. Data represent the mean of three 
determinations ± SEM. **, P < 0.01 by two-tailed Student’s t test. (h) HO15 and Myc3 cells were infected with retrovirus control or retrovirus encoding 
SIRT1. 48 h later, cells were lysed, and cell lysates were blotted with the indicated antibodies.209 SIRT1 NEGATIVELY REGULATES c-Myc • Yuan et al.
Figure 5.  SIRT1 inhibits c-Myc–induced cellular transformation. (a) Colony formation assays were performed using HO15 and Myc3 Rat1 cells infected 
with retrovirus encoding SIRT1 and SIRT1-H363Y. Colony formation was examined 2 wk later. The results shown are mean ± SEM and are representa-
tive of three independent assays. (b) Soft agar colony formation assay was performed using Myc3 Rat1 cells infected with retrovirus encoding SIRT1 and 
SIRT1-H363Y. The figure is representative of three independent assays. (c) HO15 cells were stably transfected with the indicated vectors. Cell growth was 
quantified at the indicated time. (d) Myc3 cells were transfected with Ras-encoding constructs together with vector or SIRT1-encoding constructs. Transfected 
cells were implanted into nude mice, and tumor formation was monitored. *, P < 0.05; **, P < 0.01 by two-tailed Student’s t test. (e) Model of how   
c-Myc–SIRT1 loop regulates cell growth. Ac, acetylation.JCB • VOLUME 185 • NUMBER 2 • 2009   210
described (Kim et al., 2008). c-Myc antibodies were raised by immunizing 
rabbits  with  full-length  GST–c-Myc.  Antisera  were  affinity  purified  with 
AminoLink Plus Immobilization and Purification kit (Thermo Fisher Scien-
tific). Anti-p21 antibody was provided by J. van Deursen (Mayo Clinic, 
Rochester, MN). Human TERT (H-231), Gadd45 (H-165), cyclin B1, and 
c-Myc were purchased from Santa Cruz Biotechnology, Inc. Anti–acetylated 
lysine antibody (#06-933) was purchased from Millipore, LDHA antibody 
was purchased from Cell Signaling Technology, and anti-Flag (M2) anti-
body was purchased from Sigma-Aldrich.
QRT-PCR
mRNA was isolated with PARIS kit (Applied Biosystems). QRT-PCR was per-
formed using Brilliant II SYBR Green QRT-PCR Master Mix kit (Agilent Tech-
nologies). Primers (200 nM; QIAGEN) used include rat SIRT1, human c-Myc, 
mouse TERT, mouse cyclin B1, mouse p21, mouse Gadd45, rat LDHA, rat 
mSHMT, human glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
mouse GAPDH, and rat GAPDH. Changes in gene expression were quanti-
fied based on the 2
Ct value normalized to GAPDH.
Colony and soft agar colony formation assays
Cells were plated in 60- or 35-mm dishes. After 2 wk, cells were stained 
with 2% methylene blue, and colonies were counted.
The soft agar colony formation assay was performed as described 
previously (Shim et al., 1997). In brief, Myc3 Rat1 cells were infected with 
either control, SIRT1, or SIRT1-H363Y retroviruses. Cells were plated in 
0.3% top agarose in 35-mm dishes and cultured for 2 wk. Colonies were 
counted  at  room  temperature  under  a  light  microscope  (ECLIPSE  80i; 
Nikon) using a 4× NA 0.10 objective lens (Nikon). Images were captured 
with a camera (SPOT 2 Megasample; Diagnostic Instruments, Inc.) and 
processed using SPOT software (version 4.6; Diagnostic Instruments, Inc.). 
Photoshop and Illustrator (Adobe) were used to generate figures.
Athymic nude mice tumor formation assay
Myc3 cells stably expressing H-Rasv12 together with vector or SIRT1 were 
injected subcutaneously and bilaterally into the dorsal left and right scapu-
lar areas of 5-wk-old male athymic recessive nude/nude mice (obtained 
from the National Cancer Institute) using 19-gauge needles. Each mouse 
received two injections of a 20-µl mixture of 2 ×10
6 cells in 100 µl 1× PBS 
and 100 µl growth factor–reduced Matrigel (BD). Tumor growth was moni-
tored for 6 wk, and tumor volume was calculated as 0.5 × length × height × 
width. The tumors were surgically removed, weighed, and processed.
Online supplemental material
Fig. S1 shows that reconstitution of WT SIRT1, but not catalytically inactive 
SIRT1 in SIRT1
/ cells, decreased c-Myc stability. Fig. S2 shows that SIRT1 
decreased Myc-induced LDHA and mSHMT expression. Fig. S3 shows that 
SIRT1 decreased colony formation of FBW7
+/+ and FBW7
/ cells and 
tumor formation. Online supplemental material is available at http://www 
.jcb.org/cgi/content/full/jcb.200809167/DC1.
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lism through the induction of LDHA and mSHMT (Shim et al., 
1997; Nikiforov et al., 2002), which are important for cellular 
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